3rd TRP Target Selection and Drug Design Summit 2027

Memo

Targeted radiopharmaceuticals are entering a new phase of competition and innovation. With 298 programs now in preclinical development, pipelines are expanding rapidly, yet activity remains concentrated around a relatively small number of established targets. As more programs compete for differentiation, the 3rd TRP Target Selection and Drug Design Summit (February 23–25 | Boston) is the only industry-focused meeting purpose-built for drug-developers to understand which targets, isotopes and drug design strategies will define the next generation of clinically and commercially successful radiopharmaceuticals. Join 100+ scientific, technical and strategic leaders across biotech, pharma, regulations and academia to tackle the scientific and strategic challenges underpinning radiopharmaceutical target selection and drug design. URLs:Tickets: https://go.evvnt.com/3866987-2?pid=5569Brochure: https://go.evvnt.com/3866987-3?pid=5569 Prices:Drug Developer Pricing - Conference + Workshop: USD 4507.00,Drug Developer Pricing - Conference Only: USD 3149.00,Academic Pricing - Conference + Workshop: USD 3907.00,Academic Pricing - Conference Only: USD 2749.00,Service Provider Pricing - Conference + Workshop: USD 5397.00,Service Provider Pricing - Conference Only: USD 3999.00 Speakers: Bob Seevers, Regulatory Consultant, Ex-FDA, Independent, Anneli Savinainen, Vice President and Head of Preclinical Development, Mariana Oncology/Novartis, Charles Glaus, Senior Director, Oncology Precision Medicine and Early Clinical Development, Bayer, Marianna Stamou, Director, Project Toxicologist, AstraZeneca, Vamsi Parimi, Medical Director, ADC Biomarkers, Pfizer (Former), Anthony Casarez, Co-Founder and Chief Scientific Officer, dGenThera, Anthony Casarez, Co-Founder and Chief Scientific Officer, dGenThera, Fredrik Frejd, Chief Scientific Officer, Affibody AB, Jack Hoppin, Chief Executive Officer, Ratio Therapeutics, Inc, Jeff Norenberg, Founder, CEO and Chairman, iSeek Biopharma, Keene Wei, Chief Executive Officer, Vitsgen Therapeutics, Monica Gostissa, Chief Scientific Officer, Matrisome Bio, Munir Ghesani, Chief Medical Officer, United Theranostics, Riccardo Canevari, Chief Executive Officer, RadioPharm Theranostics, Shankar Vallabhajosula, Vice President, Radiopharmaceutical Sciences, Convergent Therapeutics, Inc, Sofia Santos, Head of Biology, Nuclide Therapeutics, David Mankoff, Professor, Radiology, University of Pennsylvania, Elisabeth Li, PET Center Advanced Image Analysis Lab Lead, University of Pennsylvania, Mathew Thakur, Director, Radiopharmaceutical Research, Thomas Jefferson University, Quaovi Sodji, Assistant Professor, University of Wisconsin-Madison, Shadi Esfahani, Professor of Radiology, Director of Molecular Theranostics Laboratory, Harvard Medical School, Tadashi Watabe, Associate Professor, Osaka University, Jean-Luc Vanderheyden, PhD, Executive Director, Oncidium Foundation USA Category: Conferences Date and Time: 23rd February 2027 at 8:00 am to 25th February 2027 at 5:00 pm Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States